Studies found that the inhibition of such receptors and effectors attenuates TRPV1-induced hyperalgesia in cancer pain models, and may even ameliorate opioid resistance [143], which is quite common in cancer pain, because peripheral nerve injury, occurring during tumour cells invasion in the bone, may alter the expression of MOR and signalling proteins in the spinal cord [144,145]. This evidence concerns the gene TRPV1 and neoplasm.